Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the publication of the U.S. pivotal study results for Evolysse™ Form and Evolysse™ Smooth in the Aesthetic Surgery Journal, a leading peer-reviewed journal focusing on advances in aesthetic medicine and surgery.
The multicenter, randomized, controlled, double-blind study followed 140 patients through 12 months and evaluated the long-term safety and effectiveness of Evolysse™ Form and Evolysse™ Smooth, Cold-X™ crosslinked injectable hyaluronic acid (HA) gels, for the correction of moderate to severe dynamic facial wrinkles and folds.
Posted In: EOLS